alexa Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions.


Journal of Clinical Toxicology

Author(s): Quiralte J, Senz de San Pedro B, Florido JJ

Abstract Share this page

Abstract BACKGROUND: Controlled oral challenge with nonsteroidal anti-inflammatory drugs (NSAIDs) is the only definite way to diagnose the different clinical manifestations of NSAID sensitivity. OBJECTIVE: To evaluate the safety of selective cyclooxygenase-2 inhibitor rofecoxib in a patient population with NSAID-induced skin reactions. METHODS: We prospectively conducted single-blind, placebo-controlled, oral challenges (SBPCOCs) with rofecoxib in 15 patients with challenge-proven NSAID-induced cutaneous reactions. RESULTS: Fifteen patients (9 men and 6 women, ranging in age from 14 to 60 years) had positive SBPCOC response to at least one of the following NSAIDs: aspirin (in 46.7\% of cases), nimesulide (in 40\% of cases), and diclofenac (in the remaining 13.3\% of cases). During controlled challenges, 8 patients (53.3\%) had urticaria (1 of them with associated angioedema); 6 (40\%) had facial angioedema; and 1 (6.6\%) had nonurticarial rash. Controlled oral challenge with rofecoxib were well tolerated in all patients. CONCLUSION: Rofecoxib did not cross-react with aspirin and other NSAIDs in patient with NSAID-induced skin reactions. A tolerance observed to this drug during SBPCOCs will indicate a safe alternative in this patient-group.
This article was published in Ann Allergy Asthma Immunol and referenced in Journal of Clinical Toxicology

Relevant Expert PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version